Quarterly report pursuant to Section 13 or 15(d)

Note 4 - Acquisition (Tables)

v3.23.3
Note 4 - Acquisition (Tables)
9 Months Ended
Sep. 30, 2023
Notes Tables  
Business Acquisition, Pro Forma Information [Table Text Block]
   

For the Three Months Ended September 30, 2023

   

For the Three Months Ended September 30, 2022

 
   

(Unaudited)

   

(Unaudited)

 

Revenue

  $ 15,290,000     $ 12,775,000  
                 

Earnings

  $ 4,076,000     $ (13,777,000 )
   

For the Nine Months Ended September 30, 2023

   

For the Nine Months Ended September 30, 2022

 
   

(Unaudited)

   

(Unaudited)

 

Revenue

  $ 44,071,000     $ 39,248,000  
                 

Earnings

  $ (6,219,000 )   $ (16,511,000 )
Schedule of Business Acquisitions, by Acquisition [Table Text Block]
   

Purchase Price Allocation

 

Total purchase consideration

  $ 11,465,000  

Fair value of non-controlling interest

    15,957,000  

Total consideration

  $ 27,422,000  
         

Identifiable net assets acquired - Provisional:

       

Cash

  $ 7,352,000  

Accounts receivable, net

    6,478,000  

Accounts receivable, other

    506,000  

Inventory

    1,631,000  

Prepaid expenses

    220,000  

Property and equipment, net

    2,883,000  

Right of use assets, net

    405,000  

Intangible assets, net:

       

Trade name

    4,060,000  

Development technology

    2,560,000  

Pharmacy records

    8,100,000  

Other

    -  

Deposits

    39,000  

Accounts payable and accrued expenses

    (8,196,000 )

Notes payable and accrued interest - current portion

    (149,000 )

Lease liabilities - current portion

    (208,000 )

Notes payable - long term

    (1,173,000 )

Lease liabilities - long term

    (230,000 )

Net assets acquired

  $ 24,278,000  
         

Goodwill

  $ 3,144,000